title: AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
abstract: OBJECTIVE
  We have investigated how pre-incubating hCB(2) CHO cells with the CB(2) receptor antagonists/inverse agonists, AM630 and SR144528, affects how these and other ligands target hCB(2) receptors in these cells or their membranes.
  
  
  METHODS
  We tested the ability of AM630, SR144528 and of the CB(1) /CB(2) receptor agonists, CP55940 and R-(+)-WIN55212, to modulate forskolin-stimulated cAMP production in hCB(2) CHO cells or [(35) S]-GTPγS binding to membranes prepared from these cells, or to displace [(3) H]-CP55940 from whole cells and membranes. Assays were also performed with the CB(2) receptor partial agonist, Δ(9) -tetrahydrocannabivarin. Some cells were pre-incubated with AM630 or SR144528 and then washed extensively.
  
  
  RESULTS
  AM630 behaved as a low-potency neutral competitive antagonist in AM630-pre-incubated cells, a low-potency agonist in SR144528-pre-incubated cells, and a much higher-potency inverse agonist/antagonist in vehicle-pre-incubated cells. AM630 pre-incubation (i) reduced the inverse efficacy of SR144528 without abolishing it; (ii) increased the efficacy of Δ(9) -tetrahydrocannabivarin; and (iii) did not affect the potency with which AM630 displaced [(3) H]-CP55940 from whole cells or its inverse agonist potency and efficacy in the [(35) S]-GTPγS membrane assay.
  
  
  CONCLUSIONS
  These results suggest that AM630 is a protean ligand that can target a constitutively active form of the hCB(2) receptor (R*) with low affinity to produce agonism or neutral antagonism and a constitutively inactive form of this receptor (R) with much higher affinity to produce inverse agonism, and that the constitutive activity of whole cells is decreased less by pre-incubation with AM630 than with the higher-efficacy inverse agonist, SR144528.
  
  
  BACKGROUND
  This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
authors: Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
authors: Daniele
authors: D
authors: Bolognini
authors: Maria Grazia
authors: MG
authors: Cascio
authors: Daniela
authors: D
authors: Parolaro
authors: Roger G
authors: RG
authors: Pertwee
references: Br J Pharmacol. 2006 Sep;149(2):145-54
references: 16894349
references: Br J Pharmacol. 2011 Nov;164 Suppl 1:S1-324
references: 22040146
references: FASEB J. 2008 Jul;22(7):2311-22
references: 18267983
references: Trends Pharmacol Sci. 1995 Mar;16(3):89-97
references: 7540781
references: Handb Exp Pharmacol. 2005;(168):1-51
references: 16596770
references: Br J Pharmacol. 1999 Oct;128(3):735-43
references: 10516656
references: Br J Pharmacol. 2005 Dec;146(7):917-26
references: 16205722
references: J Biomol Screen. 2010 Dec;15(10):1238-47
references: 20811068
references: Pharmacol Rev. 2010 Dec;62(4):588-631
references: 21079038
references: Can J Physiol Pharmacol. 2006 Mar-Apr;84(3-4):287-97
references: 16902576
references: Mol Pharmacol. 2000 Dec;58(6):1412-23
references: 11093781
references: Br J Pharmacol. 2009 Sep;158(1):382-91
references: 19552692
references: Pharmacol Rev. 2002 Jun;54(2):161-202
references: 12037135
references: Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106
references: 12450575
references: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references: 4202581
references: Br J Pharmacol. 2010 Jun;160(3):677-87
references: 20590571
references: FASEB J. 2001 Mar;15(3):598-611
references: 11259378
references: Br J Pharmacol. 2008 Jan;153(2):226-39
references: 17906679
references: Br J Pharmacol. 1999 Feb;126(3):665-72
references: 10188977
references: Curr Top Med Chem. 2010;10(8):768-78
references: 20370714